XTL Biopharmaceuticals Ltd (XTLB) - Total Liabilities

Latest as of December 2024: ILA3.12 Million ILA ≈ $8.35K USD

Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has total liabilities worth ILA3.12 Million ILA (≈ $8.35K USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore XTL Biopharmaceuticals Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

XTL Biopharmaceuticals Ltd - Total Liabilities Trend (2013–2024)

This chart illustrates how XTL Biopharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Megaron SA WAR:MEG	Poland	zł10.27 Million
Sepatu Bata Tbk JK:BATA	Indonesia	Rp402.13 Billion
Kingfisher Mining Ltd AU:KFM	Australia	AU$87.66K
BTU Metals Corp V:BTU	Canada	CA$87.59K
Pearl Gull Iron Ltd AU:PLG	Australia	AU$303.09K
NCC Group plc LSE:NCC	UK	GBX136.80 Million
Good Shroom Co Inc V:MUSH	Canada	CA$1.19 Million
Jain Irrigation Systems Limited NSE:JISLDVREQS	India	Rs61.58 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down XTL Biopharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of XTL Biopharmaceuticals Ltd to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.61	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.57	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.36	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XTL Biopharmaceuticals Ltd (2013–2024)

The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	ILA3.12 Million ≈ $8.35K	+1412.14%
2023-12-31	ILA206.00K ≈ $552.28	+10.16%
2022-12-31	ILA187.00K ≈ $501.34	-85.45%
2021-12-31	ILA1.28 Million ≈ $3.45K	+405.91%
2020-12-31	ILA254.00K ≈ $680.97	+9.48%
2019-12-31	ILA232.00K ≈ $621.98	-8.30%
2018-12-31	ILA253.00K ≈ $678.28	-91.47%
2017-12-31	ILA2.97 Million ≈ $7.95K	+799.09%
2016-12-31	ILA330.00K ≈ $884.72	-24.31%
2015-12-31	ILA436.00K ≈ $1.17K	-54.82%
2014-12-31	ILA965.00K ≈ $2.59K	-21.54%
2013-12-31	ILA1.23 Million ≈ $3.30K	--

About XTL Biopharmaceuticals Ltd

TA:XTLB Israel Biotechnology

Market Cap

$4.49 Million

ILA1.67 Billion ILA

Market Cap Rank

#28880 Global

#418 in Israel

Share Price

ILA1.90

Change (1 day)

+5.56%

52-Week Range

ILA1.60 - ILA8.70

All Time High

ILA14.98